{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:35:58Z","timestamp":1793424958400,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cardiogenic shock (CS) occurs in 5\u201310% of patients with acute myocardial infarction (AMI), and the condition is associated with a 30-day mortality rate of up to 50%. Most of the AMI patients are in SCAI SHOCK stage B upon hospital arrival, but some of these patients will progression through the stages to overt shock (SCAI C-E). Around one third of patients who develop CS are not in shock at the time of hospital admission. Pro-B-type natriuretic peptide (proband) is a biomarker closely related to CS development. The aim of this study is to investigate the potential for preventing progression of hemodynamic instability by early inotropic support with low-dose dobutamine infusion administrated after revascularization in AMI patients with intermediate to high risk of in-hospital CS development.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This investigator-initiated, double-blinded, placebo-controlled, randomized, single-center, clinical trial will include 100 AMI patients (\u2265\u200918\u00a0years) without CS at hospital admission and at intermediate-high risk of in-hospital CS development (ORBI risk score\u2009\u2265\u200910). Patients will be randomized in a 1:1 ratio to a 24\u00a0h intravenous (IV) infusion of dobutamine (5\u00a0\u03bcg\/kg\/min) or placebo (NaCl) administrated after acute percutaneous coronary intervention (PCI) (&lt;\u200924\u00a0h from symptom onset). Blood samples are drawn at time points from study inclusion (before infusion, 12, 24, 36, and 48\u00a0h).\n<\/jats:p>\n                <jats:p>The primary outcome is peak plasma proBNP within 48\u00a0h after infusion as a surrogate-measure for the hemodynamic status. Hemodynamic function will be assessed pulse rate, blood pressure, and lactate within 48\u00a0h after infusion and by transthoracic echocardiography (TTE) performed after 24\u201348\u00a0h and at follow-up after 3\u00a0months. Markers of cardiac injury (troponin T and creatine kinase MB (CK-MB)) will be assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Early inotropic support with low-dose dobutamine infusion in patients with AMI, treated with acute PCI, and at intermediate-high risk of in-hospital CS may serve as an intervention promoting hemodynamic stability and facilitating patient recovery. The effect will be assessed using proBNP as a surrogate marker of CS development, hemodynamic measurements, and TTE within the initial 48\u00a0h and repeated at a 3-month follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The Regional Ethics Committee\n: H-21045751. EudraCT: 2021\u2013002028-19. ClinicalTrials.gov: NCT05350592, Registration date:\u00a02022-03-08. WHO Universal Trial Number: U1111-1277\u20138523.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-024-08567-y","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:28:27Z","timestamp":1730294907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Sarah Louise Duus","family":"Holle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim Bo","family":"Kunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hassager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Redi","family":"Pecini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Holmvang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia Evi","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Kj\u00e6rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Hartvig","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Engstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Eifer","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Thomsen","family":"L\u00f8nborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"S\u00f8holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Frydland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"8567_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/eurheartj\/ehac667","volume":"44","author":"DM Christensen","year":"2023","unstructured":"Christensen DM, Schjerning AM, Smedegaard L, Charlot MG, Ravn PB, Ruwald AC, et al. Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study. Eur Heart J. 2023;44:488\u201398. https:\/\/doi.org\/10.1093\/eurheartj\/ehac667. Cited 2024 Jun 13.","journal-title":"Eur Heart J"},{"issue":"5","key":"8567_CR2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.106.613596","volume":"117","author":"HR Reynolds","year":"2008","unstructured":"Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117(5):686\u201397.","journal-title":"Circulation"},{"issue":"1","key":"8567_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2048872617706503","volume":"7","author":"L Obling","year":"2018","unstructured":"Obling L, Frydland M, Hansen R, M\u00f8ller-Helgestad OK, Lindholm MG, Holmvang L, et al. Risk factors of late cardiogenic shock and mortality in ST-segment elevation myocardial infarction patients. Eur Heart J Acute Cardiovasc Care. 2018;7(1):7\u201315.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"11","key":"8567_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/ejhf.339","volume":"17","author":"L De Luca","year":"2015","unstructured":"De Luca L, Olivari Z, Farina A, Gonzini L, Lucci D, Di Chiara A, et al. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. Eur J Heart Fail. 2015;17(11):1124\u201332.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"8567_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ccd.28329","volume":"94","author":"DA Baran","year":"2019","unstructured":"Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv. 2019;94(1):29\u201337.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"17","key":"8567_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.jacc.2019.07.077","volume":"74","author":"JC Jentzer","year":"2019","unstructured":"Jentzer JC, van Diepen S, Barsness GW, Henry TD, Menon V, Rihal CS, et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol. 2019;74(17):2117\u201328 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31548097\/. Cited 2024 Jun 24.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"8567_CR7","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1093\/eurheartj\/ehy127","volume":"39","author":"V Auffret","year":"2018","unstructured":"Auffret V, Cottin Y, Leurent G, Gilard M, Beer JC, Zabalawi A, et al. Predicting the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: the ORBI risk score. Eur Heart J. 2018;39(22):2090\u2013102.","journal-title":"Eur Heart J"},{"key":"8567_CR8","doi-asserted-by":"publisher","unstructured":"Toth M, Vuorinen KH, Vuolteenaho O, Hassinen IE, Uusimaa PA, Leppaluoto J, et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. American J Physiol-Heart Circulatory Physiol. 1994;266(4):H1572\u201380. Available from: https:\/\/www.physiology.org\/doi\/https:\/\/doi.org\/10.1152\/ajpheart.1994.266.4.H1572.","DOI":"10.1152\/ajpheart.1994.266.4.H1572"},{"key":"8567_CR9","doi-asserted-by":"publisher","unstructured":"Tateishi J, Masutani M, Ohyanagi hhTSUMASA, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23(10):776\u201380. https:\/\/doi.org\/10.1002\/clc.4960231016.","DOI":"10.1002\/clc.4960231016"},{"issue":"9","key":"8567_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1096\/fj.02-0796fje","volume":"17","author":"JP Goetze","year":"2003","unstructured":"Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Rastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17(9):1105\u20137 Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1096\/fj.02-0796fje.","journal-title":"FASEB J"},{"issue":"6","key":"8567_CR11","doi-asserted-by":"publisher","first-page":"R1093","DOI":"10.1152\/ajpregu.1984.247.6.R1093","volume":"247","author":"JR Dietz","year":"1984","unstructured":"Dietz JR. Release of natriuretic factor from rat heart-lung preparation by atrial distension. American J Physiol Regulatory Integr Comparative Physiol. 1984;247(6):R1093\u20136.","journal-title":"American J Physiol Regulatory Integr Comparative Physiol"},{"issue":"1","key":"8567_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0002-8703(98)70338-2","volume":"135","author":"N Nagaya","year":"1998","unstructured":"Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J. 1998;135(1):21\u20138.","journal-title":"Am Heart J"},{"issue":"19","key":"8567_CR13","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1161\/01.CIR.97.19.1921","volume":"97","author":"AM Richards","year":"1998","unstructured":"Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97(19):1921\u20139.","journal-title":"Circulation"},{"issue":"1","key":"8567_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ahj.2009.11.001","volume":"159","author":"R Jarai","year":"2010","unstructured":"Jarai R, Huber K, Bogaerts K, Droogne W, Ezekowitz J, Granger CB, et al. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and thrombolysis in myocardial infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. Am Heart J. 2010;159(1):131\u201340.","journal-title":"Am Heart J"},{"issue":"11","key":"8567_CR15","first-page":"CD009669","volume":"11","author":"K Uhlig","year":"2020","unstructured":"Uhlig K, Efremov L, Tongers J, Frantz S, Mikolajczyk R, Sedding D, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2020;11(11):CD009669.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"8567_CR16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0002-9149(77)80170-7","volume":"39","author":"TA Gillespie","year":"1977","unstructured":"Gillespie TA, Ambos HD, Sobel BE, Roberts R. Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol. 1977;39(4):588\u201394 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914977801707.","journal-title":"Am J Cardiol"},{"issue":"3","key":"8567_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237\u201369.","journal-title":"Eur Heart J"},{"issue":"1","key":"8567_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/01.RES.36.1.185","volume":"36","author":"RR Tuttle","year":"1975","unstructured":"Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975;36(1):185\u201396.","journal-title":"Circ Res"},{"key":"8567_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.107.728840","volume":"118","author":"CB Overgaard","year":"2008","unstructured":"Overgaard CB, D\u017eav\u00edk V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118:1047\u201356.","journal-title":"Circulation."},{"issue":"38","key":"8567_CR20","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"2","key":"8567_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"issue":"9","key":"8567_CR22","doi-asserted-by":"publisher","first-page":"e048312","DOI":"10.1136\/bmjopen-2020-048312","volume":"11","author":"PD Mark","year":"2021","unstructured":"Mark PD, Frydland M, Helgestad OKL, Holmvang L, M\u00f8ller JE, Johansson PI, et al. Sex-specific mortality prediction by pro-C-type natriuretic peptide measurement in a prospective cohort of patients with ST-elevation myocardial infarction. BMJ Open. 2021;11(9):e048312.","journal-title":"BMJ Open"},{"issue":"6","key":"8567_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1515\/CCLM.2010.164","volume":"48","author":"S Buchner","year":"2010","unstructured":"Buchner S, Debl K, Barlage S, Griese D, Fredersdorf S, Jeron A, et al. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome. Clin Chem Lab Med. 2010;48(6):875\u201381 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20441480\/. Cited 2024 Mar 19.","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"8567_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/2048872619896063","volume":"9","author":"M Frydland","year":"2020","unstructured":"Frydland M, M\u00f8ller JE, Lindholm MG, Hansen R, Wiberg S, Lerche Helgestad OK, et al. Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2020;9(6):557\u201366.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"8567_CR25","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"8567_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"4","key":"8567_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/j.1875-9114.1989.tb04133.x","volume":"9","author":"TC Majerus","year":"1989","unstructured":"Majerus TC, Dasta JF, Bauman JL, Danziger LH, Ruffolo RR. Dobutamine: ten years later. Pharmacotherapy\u202f: the journal of human pharmacology and drug therapy. 1989;9(4):245\u201359.","journal-title":"Pharmacotherapy : the journal of human pharmacology and drug therapy"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08567-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:31:21Z","timestamp":1730295081000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08567-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8567"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08567-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and its subsequent amendments have been reviewed and approved by the sponsor, the Regional Ethical Committee (H-21045751) and the Danish Medicines Agency (2021073315) with respect to scientific content and compliance with applicable research and human subjects\u2019 regulations.Informed consent forms, patient information, recruitment materials, and other requested documents have likewise been reviewed and approved by the Regional Ethical Committee. Written, informed consent to participate is obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable\u2014no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"731"}}